Skip to content
An Initiative of AVAC
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 1 - 10 of 342

Selected Filters:
26 July 2024

Online Pharmacy PrEP and PEP: Technical considerations and learnings from Kenya

This document, developed by PATH, is intended as a how-to implementation guide for providing oral pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) via online pharmacy service delivery (ePrEP/ePEP) based on learnings and evidence from the ePrEP Kenya pilot study that ran from October 2022 through July 2024. The guide was developed to support ministries of…

Research, Service Delivery

Document
24 July 2024

WHO Guidelines for HIV Post-exposure Prophylaxis

These guidelines developed by the World Health Organisation outline the latest recommendations and evidence on use of post-exposure prophylaxis (PEP).

Normative Guidance/Policies

Document
23 July 2024

Malawi Health Sector Strategic Plan III, 2023-2030

This new Health Sector Strategic Plan builds on Malawi’s 2030 targets for Universal Health Coverage.

Normative Guidance/Policies

Document
22 July 2024

The urgency of now: AIDS at a crossroads- UNAIDS 2024 Global AIDS Update

This report from UNAIDS, released in July 2024, outlines progress made towards the 2025 milestones to end the AIDS pandemic, and recommendations to sustain the gains beyond 2030.

Monitoring & Evaluation, Service Delivery

Document
22 July 2024

Coordinating Implementation Science: PrEP and the Role of HIV Self-Testing

This document summarises key takeaways from a June 2024 BioPIC Think Tank to review and discuss opportunities and challenges in the scale-up of HIV self-testing for PrEP initiation and continuation.

Research, Service Delivery, Testing

Document
19 July 2024

Coordinating Implementation Science for CAB for PrEP: HIV Testing

This document summarises key takeaways from a June 2024 BioPIC Think Tank to review and discuss emerging issues around cabotegravir (CAB) for PrEP implementation and HIV testing algorithms.

Research, Service Delivery, Testing

Document
19 July 2024

Consolidated Guidelines on Differentiated HIV Testing Services

These guidelines, developed by WHO, outline a public health approach to strengthening and expanding HIV testing services. They present and discuss key updates to previous HIV testing guidelines, with a focus on new evidence, new recommendations, good practices and operational considerations that respond to the changing needs of national programmes, including guidance on HIV testing…

Normative Guidance/Policies, Testing

Document
16 July 2024

Pre-Exposure Prophylaxis and Adolescent Girls and Young Women in Eastern and Southern Africa: The latest insights

Eastern and southern Africa (ESA) is the world’s most heavily HIV-impacted region, with adolescent girls and young women (AGYW) disproportionately affected. To support the scale-up of PrEP amongst AGYW in ESA, in September 2021 UNICEF and partners released the implementation brief “Improving the Quality of Pre-Exposure Prophylaxis Implementation for Adolescent Girls and Young Women in…

Research, Service Delivery

Document
15 July 2024

Strengthening and Harmonising PrEP Indicators

Experience gained from the implementation and analysis of PrEP programs reveals significant limitations in current indicators for global PrEP monitoring. Metrics focused on numbers of ‘people receiving PrEP’ struggle to track individual clients, overlook method switching and discontinuous patterns of PrEP use, and present challenges in using indicator data to estimate PrEP coverage and program…

Monitoring & Evaluation

Presentation
8 July 2024

The Lens on LEN

In late June 2024, Gilead Sciences announced an early review of the data of the PURPOSE 1 trial by an independent monitoring board, which found that injectable lenacapavir (LEN) provided as prevention was safe and highly effective against HIV. The product is being tested among 5,300 HIV-negative cisgender women ages 16-25 in Uganda and South…

Research

Document